CA3171025A1 - Fibroblast activation protein ligands for targeted delivery applications - Google Patents

Fibroblast activation protein ligands for targeted delivery applications

Info

Publication number
CA3171025A1
CA3171025A1 CA3171025A CA3171025A CA3171025A1 CA 3171025 A1 CA3171025 A1 CA 3171025A1 CA 3171025 A CA3171025 A CA 3171025A CA 3171025 A CA3171025 A CA 3171025A CA 3171025 A1 CA3171025 A1 CA 3171025A1
Authority
CA
Canada
Prior art keywords
moiety
cancer
compound
conjugate
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171025A
Other languages
English (en)
French (fr)
Inventor
Ilaria BIANCOFIORE
Samuele CAZZAMALLI
Sheila Dakhel Plaza
Etienne J. DONCKELE
Jacopo MILLUL
Florent SAMAIN
Eleonore SCHMIDT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philochem AG
Original Assignee
Philochem AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philochem AG filed Critical Philochem AG
Priority claimed from PCT/EP2021/053494 external-priority patent/WO2021160825A1/en
Publication of CA3171025A1 publication Critical patent/CA3171025A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3171025A 2020-02-12 2021-02-12 Fibroblast activation protein ligands for targeted delivery applications Pending CA3171025A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20157036 2020-02-12
EP20157036.3 2020-02-12
EP20172953.0 2020-05-05
EP20172953 2020-05-05
EP20202856.9 2020-10-20
EP20202856 2020-10-20
PCT/EP2021/053494 WO2021160825A1 (en) 2020-02-12 2021-02-12 Fibroblast activation protein ligands for targeted delivery applications

Publications (1)

Publication Number Publication Date
CA3171025A1 true CA3171025A1 (en) 2021-08-19

Family

ID=83225945

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171025A Pending CA3171025A1 (en) 2020-02-12 2021-02-12 Fibroblast activation protein ligands for targeted delivery applications

Country Status (8)

Country Link
JP (1) JP2023514275A (ko)
KR (1) KR20220154111A (ko)
CN (1) CN115335370A (ko)
AU (1) AU2021220663A1 (ko)
BR (1) BR112022016049A2 (ko)
CA (1) CA3171025A1 (ko)
IL (1) IL295571A (ko)
MX (1) MX2022009931A (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116925041A (zh) * 2023-06-12 2023-10-24 上海交通大学医学院附属仁济医院 靶向成纤维细胞激活蛋白的氟标记放射性药物前体、放射性标记化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006128A (es) * 2017-12-15 2020-09-21 Praxis Biotech LLC Inhibidores de la proteina de activacion de fibroblastos.
AU2019219057B2 (en) * 2018-02-06 2022-11-24 Universität Heidelberg FAP inhibitor

Also Published As

Publication number Publication date
KR20220154111A (ko) 2022-11-21
AU2021220663A1 (en) 2022-10-06
JP2023514275A (ja) 2023-04-05
CN115335370A (zh) 2022-11-11
BR112022016049A2 (pt) 2022-11-16
MX2022009931A (es) 2022-09-12
IL295571A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
EP3891138B1 (en) Fibroblast activation protein ligands for targeted delivery applications
US20230381324A1 (en) Small molecule drug conjugates
RU2714933C2 (ru) Конъюгаты var2csa-лекарственное средство
US20240148916A1 (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
EP4043452A1 (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
WO2023144379A1 (en) High-affinity ligands of fibroblast activation protein for targeted delivery applications
CA3171025A1 (en) Fibroblast activation protein ligands for targeted delivery applications
US20230147962A1 (en) Fibroblast activation protein ligands for targeted delivery applications
CA3198066A1 (en) Reactive conjugates
WO2024094827A1 (en) Carbonic anhydrase ix ligands for targeted delivery applications
CN116917278A (zh) 用于靶向递送应用的二价成纤维细胞活化蛋白配体
WO2024052333A1 (en) Multivalent fibroblast activation protein ligands for targeted delivery applications
WO2023088236A1 (zh) Mt1-mmp的双环肽配体及其缀合物
EA046139B1 (ru) Конъюгаты лиганда-лекарственного средства в качестве субстратов для селективного расщепления под действием экзопептидазной активности катепсина b